David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...

AbbVie is among an elite group of companies known as Dividend Kings, which have raised their payouts for more than 50 years.

Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...